Neoplasm of thorax

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

This early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and atta…

This phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…

This phase 3 trial tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. Abo…

Researchers are testing an experimental oral drug called ND-003 in Chinese patients with advanced solid tumors that have worsened after standard treatment or have no standard options left. ND-003 blocks two proteins, NTRK and RET, that can drive cancer growth when altered. The ph…

This study tests a combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo helps control the cancer longer than standard tre…

This study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…

This study tests whether giving the immunotherapy drug pembrolizumab every 12 weeks works as well as the standard every 3 weeks in people with non-small cell lung cancer who are already benefiting from the drug. The goal is to see if fewer treatments can keep the cancer under con…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

Researchers are running a first-in-human Phase 1 trial of gamitrinib, an experimental drug that targets mitochondria in cancer cells, in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find the highest dose people …

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

Researchers are testing whether combining sitravatinib and tislelizumab, with or without nab-paclitaxel, can shrink tumors in people with locally recurrent or metastatic triple-negative breast cancer. The trial enrolls about 98 adults whose cancer is estrogen-receptor, progestero…

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…

Researchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…

This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…

This phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…

This study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…

This study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…

This early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…

This phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…

This study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.

Researchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…

This Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycle…

Researchers compare two schedules of partial breast irradiation after breast-conserving surgery in women with low-risk early breast cancer. One group receives radiation daily for one week, the other for three weeks. The trial measures breast appearance three years later and track…

This phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…

This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…

Researchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This trial tests whether women with advanced breast cancer (cN3) who had chemotherapy before surgery can safely skip an extra radiation dose to lymph nodes that no longer show signs of cancer. Half of the participants receive the standard extra radiation boost, while the other ha…

This early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

Researchers test whether giving mitomycin plus carboplatin before surgery helps people with BRCA1 or BRCA2 mutations and locally advanced triple-negative breast cancer. The trial compares this combination, followed by paclitaxel, against standard chemotherapy. About 30 adults wit…

This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…

This study compares two surgical approaches for breast cancer: one that removes extra tissue around the tumor (routine cavity shave margins) and one that uses a special device (Savi Scout®) to guide removal of only suspicious margins. About 204 women with early-stage breast cance…

This early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…

This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …

This study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…

This early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…

Researchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…

This study will track 600 people in Korea with advanced breast cancer who are already being prescribed Talzenna. Researchers will watch for side effects and see how well the drug works in everyday medical practice, not in a strict research setting. The goal is to confirm the drug…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This program provides early access to divarasib, an experimental oral drug designed to target the KRAS G12C mutation found in some non-small cell lung cancers. It is open to adults with advanced or metastatic disease that has progressed after at least one prior standard treatment…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase II trial studies whether giving radiation therapy before surgery can shrink hormone receptor-positive, HER2-negative breast tumors. About 25 participants will receive radiation followed by breast surgery. The goal is to see if this approach reduces the amount of normal…

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This study tests a new dye called Magtrace that stays in the lymph nodes for weeks. For women with non-invasive breast cancer (DCIS) having a mastectomy, this dye may allow doctors to safely delay lymph node removal until after the breast tissue is checked for hidden invasive can…

This study tests a new drug called giredestrant in people with a type of advanced breast cancer (ER-positive, HER2-negative) that has progressed after prior treatments. About 303 participants will receive either giredestrant or another standard hormone therapy chosen by their doc…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabi…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This study tests whether adding an experimental drug (ST-067) to standard CAR T-cell therapy can safely and effectively treat adults with large B-cell lymphoma that has returned or not responded to prior treatments. About 33 participants will receive the combination to see if it …

This early study tests whether giving nivolumab (an immunotherapy) along with standard chemotherapy before surgery is safe and feasible for people with malignant pleural mesothelioma. The main goal is to see if this approach delays surgery by more than 30 days. 22 participants wi…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-phase trial is testing whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET alterations. Only 3 adults with advanced disease that cannot be surgically removed are enrolled. The main goal is to check safety and see…

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This phase 3 trial tests a daily pill called osimertinib (AZD9291) against a placebo in 682 people with a specific type of lung cancer (EGFR-mutated, stages IB to IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can delay or prevent the cancer from…

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This Phase II trial tests whether adding olaparib to durvalumab helps keep stage IV non-small cell lung cancer from growing after initial chemotherapy. About 400 patients whose cancer did not worsen on standard chemo plus durvalumab will receive either the combination or durvalum…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plu…

This Phase 3 trial is testing a new drug called sacituzumab tirumotecan (MK-2870) against standard platinum-based chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted t…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This phase 2 trial tests a combination of the targeted drug polatuzumab vedotin with standard chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide) as an initial salvage therapy for patients with diffuse large B-cell lymphoma that has relapsed or not responded to treat…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase 4 study is testing the safety of trastuzumab deruxtecan, a targeted antibody-drug combination, in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already received at least one prior anti-HER…

This early-phase trial tests a combination of two drugs, cyclophosphamide and veliparib, in people with HER2-negative breast cancer that has spread or cannot be surgically removed. The main goal is to find the safest dose and check for side effects. Up to 35 participants will rec…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…

This phase 2 trial tests whether adding tucatinib to standard drugs trastuzumab and capecitabine can shrink tumors in people with advanced HER2+ breast cancer who have already tried several treatments. About 66 participants will receive the three-drug combination. The main goal i…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. Abo…

This early-phase trial tests a two-step treatment for advanced breast cancer that cannot be cured with surgery or radiation. First, patients receive a drug called talazoparib alone, then both talazoparib and avelumab together. The main goal is to check safety and side effects, wh…

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This phase 3 trial tests whether adding nivolumab to standard chemo-immunotherapy improves outcomes for people with newly diagnosed primary mediastinal B-cell lymphoma. About 244 participants will receive either the combination or standard therapy alone. The main goal is to see i…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

Researchers are testing an experimental antibody-drug conjugate called TQB2102 in people with recurrent or metastatic breast cancer that has low levels of the HER2 protein. The trial enrolls about 542 adults who have not yet received chemotherapy for their advanced disease. Parti…

This phase 3 trial tests whether adding pembrolizumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer. About 672 participants will receive either the drug combo or a pla…

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have n…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (acasunlimab and pembrolizumab) works better than the standard chemotherapy docetaxel for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. …

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This study tests a drug called disitamab vedotin in 100 adults with advanced breast cancer that has spread and is hard to treat. Participants must have tumors with HER2 protein and have had prior treatment. They receive the drug into a vein every two weeks. Researchers will check…

This study offers continued treatment with capmatinib for people with advanced solid tumors that depend on a protein called cMET. It includes 29 participants who were already benefiting from capmatinib in a previous Novartis trial. The main goal is to monitor long-term safety and…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

Researchers are reviewing medical records to see how well pyrotinib works and how safe it is in people with HER2-positive advanced breast cancer whose disease worsened after treatment with trastuzumab and pertuzumab. The study includes about 200 patients in China who received pyr…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…

This phase 3 trial tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without the disease worsening. Participants first receive standard induction chemo-immunotherapy, then those with stab…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study provides continued access to the cancer drug palbociclib (IBRANCE) for up to 35 patients with breast or head and neck cancer who have already benefited from it in earlier Pfizer trials. Participants will keep taking their current treatment combination, which may includ…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This phase 3 trial tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) in 868 women with HER2-positive breast cancer that has returned or spread. The goal is to see if the new approach can dela…

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests a system called CONCURxP that uses a smart pill dispenser (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills as prescribed. About 410 patients will be split into two groups: one gets the full system…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This large study is testing several targeted therapies and immunotherapies for people with advanced non-small cell lung cancer. Instead of a tissue biopsy, a simple blood test is used to find specific genetic changes in the cancer. The goal is to see if matching the right drug to…

This study tests a daily pill called adagrasib in 68 patients with a specific type of advanced lung cancer (KRAS G12C mutation) who are either 70 or older or have poor physical health. The goal is to see if the drug can shrink tumors or stop them from growing. Patients take the m…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This study tests whether precisely targeted radiation (SBRT) can treat a few growing cancer spots in patients with metastatic breast cancer, allowing them to stay on their current systemic therapy instead of switching to a new drug. Researchers will also look at whether circulati…

This phase 3 trial tests whether adding the drug palbociclib to standard hormone therapy can help prevent breast cancer from coming back in people with a specific type of breast cancer (HR+/HER2-). About 405 participants who had surgery for a local or regional recurrence will rec…

This phase 2 trial tests whether adding two drugs (durvalumab and ceralasertib) after standard chemo-immunotherapy can help control extensive-stage small cell lung cancer. About 30 people who have not had prior treatment will receive the combination. The main goal is to see how l…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This Phase 3 trial tests whether giving one type of chemotherapy before another, before surgery, changes the chances of staying cancer-free in people with locally advanced HER2-negative breast cancer. Participants receive either a taxane (docetaxel or paclitaxel) first, followed …

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors have been completely removed by surgery. The goal is to see if BAT3306 works similarly as an additional treatment to help keep the cancer fr…

This study tests whether injecting a very dilute hydrogen peroxide solution directly into breast tumors can make standard radiotherapy more effective. Researchers are enrolling 184 adults with locally advanced or recurrent breast cancer. Participants will receive injections twice…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This study tests a new oral drug, vepdegestrant, combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 37 adults will take both pills daily at home, with clinic visits every 4 weeks, to see if the comb…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This phase III trial tests whether a structured weight loss program can lower the risk of breast cancer recurrence in overweight or obese women who have been treated for early-stage breast cancer. Researchers will compare women who join the program with those who do not, tracking…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This trial studies women with breast cancer who need a mastectomy, radiation, and immediate breast reconstruction using their own abdominal tissue (DIEP flap). The goal is to compare giving radiation before surgery versus after surgery. Researchers will measure patient satisfacti…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study looks at the long-term safety of a drug called TOL2506, which suppresses ovarian function, in people with hormone receptor-positive (HR+) breast cancer. It includes premenopausal women and men who already completed a previous study. Participants will take TOL2506 along…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…

This phase 3 study tests whether adding the targeted drug amivantamab to standard chemotherapy helps people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 308 participants will receive either the combination or chemotherapy a…

This trial tests whether adding enzalutamide, a drug used for prostate cancer, to the standard hormone therapy fulvestrant helps women with a certain type of breast cancer. The study includes postmenopausal women with ER+/Her2- breast cancer who will receive the treatment for abo…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…

This phase 1 trial tests whether a personalized aerobic exercise program, including supervised walking sessions done remotely, can be safely added to the usual first-line hormone therapy for metastatic breast cancer. Researchers want to see if exercise helps delay the development…

This early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it…

This study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This trial tests whether radiation therapy alone can control breast cancer that has spread to nearby lymph nodes as well as surgery to remove those nodes. Women with stage II or III breast cancer who still have cancer in their sentinel lymph node after chemotherapy are randomly a…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study tests a new form of the drug amivantamab that can be given as a shot under the skin, combined with the pill lazertinib, for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after prior treatments. The goal …

This trial is testing whether combining the targeted drug trastuzumab with either oral chemotherapy or hormone therapy can effectively treat stage I HER2-positive breast cancer. The study includes women aged 18-70 with small, lymph-node-negative tumors, divided into two groups ba…

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it …

This phase 3 trial is comparing an experimental targeted drug called adagrasib (MRTX849) with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has already been treated. The study aims to see if adagr…

This Phase 3 trial is testing a new daily pill called camizestrant against standard hormone therapies (like tamoxifen or aromatase inhibitors) in 5,500 people with ER+/HER2- early breast cancer who have a moderate-to-high risk of the cancer returning. Participants take the drug f…

This trial tests whether giving the immunotherapy drug durvalumab before surgery can help women with early, small triple negative breast cancer. Participants receive two infusions of durvalumab, then either proceed to surgery or, if needed, additional standard therapy. The study …

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This phase 2 trial tests whether adding plinabulin to a standard combination of pembrolizumab and docetaxel can shrink tumors or slow disease progression in people with metastatic non-small cell lung cancer that has worsened after prior immunotherapy. About 47 adults with advance…

This phase II trial is testing whether a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and fulvestrant (a hormone blocker)—can slow or stop the growth of a specific type of advanced breast cancer. The study enrolls people with ER-positiv…

This trial tests whether precisely targeted radiation (SABR) to a small number of growing tumors, while continuing current drug therapy, can delay overall disease progression in people with metastatic non-small cell lung cancer. About 68 participants whose cancer has started to g…

This phase 3 trial is testing an experimental oral drug called imlunestrant, alone or combined with abemaciclib, against standard hormone therapies for people with ER+/HER2- advanced or metastatic breast cancer that has worsened after prior hormone treatment. The study aims to se…

This study tests a drug called sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has worsened after chemotherapy. The goal is to see how well the drug shrinks tumors and to find biological markers that predict response. Participants recei…

This trial tests whether placing a small marker clip into a breast tumor without ultrasound guidance (using touch alone) is as accurate, safe, and cost-effective as using ultrasound. The study involves 50 women with palpable breast tumors who will receive neoadjuvant chemotherapy…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study looks at whether a 16-20 week exercise and coaching program can reduce inflammation and protect blood vessel health in Black and White women undergoing chemotherapy for breast cancer. Researchers will measure fitness, blood vessel function, and quality of life. The goa…

This trial tests whether removing the lung tumor before the lymph nodes, or the lymph nodes before the tumor, leads to better long-term survival in people with early-stage non-small cell lung cancer. About 620 patients will be randomly assigned to one of the two sequences. The st…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This study tests whether giving olaparib (a PARP inhibitor) alone or combined with durvalumab (an immunotherapy) before surgery can eliminate or shrink tumors in people with BRCA-mutated, HER2-negative early breast cancer. Participants receive one of the two treatments for 4–6 mo…

This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as sta…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This early-stage trial is testing whether focused ultrasound (sound waves aimed at tumors) combined with a low dose of the chemotherapy drug gemcitabine can boost the immune system's ability to fight early breast cancer. About 32 participants will receive either ultrasound, low-d…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests whether using a sensitive blood test (MRD) to guide follow-up treatment can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant stage III NSCLC). Participants first receive a targeted pill (aumolertinib), then a team of doctors d…

This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study looks at whether surgically removing the primary breast tumor (along with standard chemotherapy) helps women with oligometastatic breast cancer—cancer that has spread to only a few spots in the body—live longer. About 110 women in Pakistan will either receive surgery p…

This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 2…

This phase 2 trial is testing whether a combination of ribociclib (Kisqali) and letrozole can safely replace chemotherapy for people with high-risk ER+/HER2- breast cancer. About 1100 participants will first receive the drug combo before surgery. If their tumor shows a low risk o…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This study looks at whether a targeted therapy called palbociclib, taken for 2 years alongside standard hormone therapy, can help prevent breast cancer from coming back in older patients with high-risk ER+/HER2- early breast cancer. The goal is to offer an effective alternative t…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the s…

This study tests a modified radiation schedule for women aged 50 and older with early-stage, low-risk breast cancer. Instead of the standard every-other-day treatment over 10 days, participants receive five daily radiation sessions with a slightly lower dose each day. The goal is…

This Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…

This phase 2 trial tests giving chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug nivolumab before surgery for people with Pancoast tumors, a rare type of lung cancer. After surgery, additional treatment is tailored based on whether the tumor was fully removed…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This phase 3 trial compares giving hormone therapy (aromatase inhibitors) at the same time as chemotherapy versus after chemotherapy in 1000 postmenopausal women with early breast cancer. The goal is to see which timing better prevents the cancer from coming back over 15 years. P…

This study tests whether contrast-enhanced mammography (CEM) — a mammogram with an iodine dye injection — can find breast cancer more accurately than standard mammography. Researchers will compare CEM with other imaging methods in 100 women who have suspicious breast findings and…

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

Radiation teams use cone beam CT scans to line up patients with the treatment beam, but standard images are not clear enough to map tumors or calculate doses. This study tests whether a new imaging system called HyperSight, built into the TrueBeam radiotherapy machine, can produc…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This trial tests whether a blood test that detects circulating tumor DNA (ctDNA) can predict when advanced non-small cell lung cancer might progress in people who have already benefited from first-line immunotherapy for at least 12 months. Researchers will follow 100 participants…

This early-stage trial is testing whether a new radioactive imaging agent, called [99mTc]Tc-DARPinEc1-G3C, can safely and effectively visualize breast cancer tumors using SPECT/CT imaging. The study involves about 10 people with primary triple-negative or luminal breast cancer. P…

This study tests a new PET imaging tracer called [18F]F-AraG to see if it can spot activated T-cells inside non-small cell lung cancer tumors. Researchers will scan about 10 patients with resectable lung cancer, then compare the tracer's uptake with lab analysis of the removed tu…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…

This trial tests whether tomosynthesis (a 3D X-ray technique) combined with synthetic 2D images can reduce the number of advanced and interval breast cancers compared to standard digital mammography. Over 10,000 women scheduled for routine screening will be randomly assigned to o…

This study aims to improve early detection of lung cancer in Asian women who have never smoked, a group at higher risk but not covered by standard screening guidelines. Participants receive up to three low-dose CT scans and a blood test designed to spot early signs of cancer. Res…

This study is testing whether a simple breath test can tell if a woman has breast cancer. Researchers are collecting breath samples from 1000 women — half with breast cancer and half without — and analyzing them with a mass spectrometer. The goal is to see if the chemical signatu…

This phase 2 study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with a type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolled 68 partic…

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…

Researchers are testing whether a 14-gene test can identify people with early-stage non-squamous non-small cell lung cancer who are at higher risk of the cancer returning after surgery. Patients whose tumors are completely removed and who test as intermediate or high risk are ran…

This study tests whether mobile lung cancer screening units can increase participation among rural adults aged 50 to 80 who smoke or quit within the last 15 years. Researchers will measure how many people get screened and whether their knowledge about lung cancer changes. The goa…

This phase 3 trial is comparing two types of mammograms—standard 2D digital mammography and newer 3D tomosynthesis—to see which is better at finding advanced breast cancers early. Over 108,000 women are taking part, and researchers will track cancer diagnoses over 4.5 years. The …

This study tests whether a 6-month program combining Bollywood-style dance classes and a fitness tracker can increase physical activity and improve metabolic health in South Asian Indian immigrant women aged 40-65 who are not very active. The goal is to see if this culturally tai…

This study tests whether a mobile application can help breast cancer survivors prevent lymphedema, a common and often permanent swelling of the arm after surgery. Participants who had breast cancer surgery at least one month ago will be randomly assigned to use the app or receive…

This pilot study tests whether a smartphone app called AmDTx can help lung cancer patients manage anxiety before and after surgery. The app includes mindfulness training and a relaxing puzzle game. Only 6 participants are enrolled, and the main goal is to see if people will actua…

This study looks at whether massage therapy can reduce nerve problems like pain, numbness, and tingling caused by chemotherapy in people with breast or digestive system cancers. About 90 participants will receive massage sessions to see if it improves symptoms and quality of life…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

This study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fati…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study aims to develop and test a shortened version of Mindfulness-Based Cognitive Therapy (MBCT) to improve mood in older African American/Black women who have had breast cancer and now have mild to moderate depression. About 23 participants will attend group sessions and re…

This study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…

This study tests a new tool called the Buckeye Quit Stick to help smokers with lung cancer quit. The stick replaces the hand-to-mouth habit of smoking without using medicine. About 30 adults will try it for 6 months to see if it helps them stay smoke-free.

This study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…

This study looks at whether hypnosis can help women with early-stage breast cancer relax during surgery, possibly reducing the need for general anesthesia. About 50 women will try hypnosedation, a technique that uses words and images to keep them calm and awake while numb. The go…

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests whether a remotely delivered program that combines mindfulness, physical activity tracking, and social support is acceptable and feasible for people with metastatic breast cancer. The program lasts 8-12 weeks and includes a wearable activity tracker and weekly ch…

Researchers are testing a three-part art therapy program for women aged 45 and younger who have had breast cancer surgery. The program combines body, voice, and mind exercises. The trial measures changes in insomnia severity and overall physical, mental, and social wellbeing. It …

This study tests whether a tailored physical activity program can help lymphoma and breast cancer patients preserve their exercise ability, heart function, memory, and quality of life while undergoing cancer treatment. About 110 adults aged 18-85 with Hodgkin or non-Hodgkin lymph…

This study tests a 5-week computer-based memory training program for breast cancer survivors who have memory and attention problems after chemotherapy. Sixty women will be randomly assigned to either the full working memory training or a less challenging version. The goal is to s…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study tests whether an interactive 3D tool, used during a standard surgical consultation, helps women feel more satisfied with the information they receive about breast reconstruction options. Researchers will also check if the tool improves satisfaction with their breasts a…

This pilot study tests a decision aid designed to help women with early-stage breast cancer choose between lumpectomy and mastectomy. The tool uses quality-of-life data from past patients to help women weigh the risks and benefits based on their own values. Researchers will see i…

This study tests whether a 16-week high-intensity interval training (HIIT) program on a stationary bike can improve thinking, memory, and heart health in women undergoing chemotherapy for breast cancer. Thirty participants will be randomly assigned to either HIIT or a stretching …

This study tests a 3-month intermittent fasting weight loss program in 36 adults who have completed treatment for breast cancer and are overweight or obese. Participants follow a 4:3 fasting schedule (3 modified fast days per week) and aim for 150 minutes of physical activity wee…

This trial tests whether a 12-week supervised aerobic exercise program can improve physical function, quality of life, and cognitive function in women who have finished treatment for early-stage breast cancer and are in remission. Researchers will measure blood levels of three bi…

This study tests whether a personalized support program led by a nurse can help prevent memory and thinking problems that often occur after chemotherapy in women with non-metastatic breast cancer. Fifty women will receive regular face-to-face and telephone interviews over 9 month…

This trial asks whether starting sexual health support early and systematically helps women with localized breast cancer feel better about their sexual well-being compared to waiting until they ask for help. Women aged 18 and older who are beginning treatment with surgery will re…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This study tests whether structured hypnotherapy sessions can improve quality of life for women with breast cancer undergoing chemotherapy. Participants in the intervention group receive 10 hypnotherapy sessions alongside standard care, while the control group receives standard c…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This study looks at whether a structured educational program, added to usual care, can help people who have surgery for lung cancer. The goal is to see if it improves how well they accept their disease, their quality of life, and their pain levels. About 160 participants are spli…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This study looks at whether starting rehabilitation early or later helps reduce cancer-related fatigue in people with lung cancer. About 31 patients with stage II or III lung cancer will take part. The goal is to see if the rehab program is practical and helpful for improving ene…

This study tests whether a type of pain education that teaches the brain's role in pain, combined with motivational interviewing, can reduce chronic pain in breast cancer survivors. 156 women who have finished primary treatment and still have pain will be randomly assigned to thi…

This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

Researchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…

This study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more pe…

This study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…

Researchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…

This study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…

This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…

This study tests whether giving smokers and former smokers a personalized risk report (based on clinical and genetic factors) helps doctors order lung cancer screening and helps patients follow through. About 915 participants will be randomly assigned to usual care or one of two …

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study looks at skin and soft tissue removed during breast implant surgery after mastectomy. Researchers want to see if the physical properties of the tissue can help predict complications like implant loss. The goal is to better understand risks and improve surgical outcomes…

This pilot study is testing whether wearable activity trackers, like fitness watches, can help monitor fatigue in people with pancreatic or breast cancer who are undergoing treatment. Researchers want to see if patients will use the device daily and find it easy to use. The study…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…

This study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…

Tumours in the head, neck, or chest can narrow or distort the airway, and standard difficult-airway guidelines offer little cancer-specific advice. This study asks an international panel of anaesthesiologists, intensive care doctors, lung specialists, head and neck surgeons, and …

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study looks at whether a special type of breast scan, called molecular breast imaging, can help doctors predict how well chemotherapy is working in women with invasive breast cancer. About 96 women will get the scan before, during, and after treatment. The goal is to see if …

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study looks at what breast cancer survivors and their family members know about chemicals in personal care products that might affect hormones. Researchers also want to see if there is a link between excess weight and these chemicals. About 30 people from the Acres Home comm…

This study asks breast cancer patients about their thoughts on screening for lymphedema, a common side effect where the arm becomes swollen and painful after treatment. Researchers use a device called a perometer to measure arm size before and after surgery. The goal is to see if…

This study tests a computer app that shows personalized images of what breast reconstruction might look like after surgery. The goal is to help patients make more informed decisions and reduce confusion. About 35 adults planning mastectomy and immediate reconstruction at MD Ander…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study looks at whether it is practical to give women recovering from breast-conserving surgery or mastectomy with reconstruction immediate feedback from their recovery surveys. The tool, called BREAST-Q REACT, shows scores on physical well-being and arm function and offers t…

Breast cancer patients often face uncertainty about how surgery or radiation will affect their appearance. This trial compares a standard approach, where doctors explain outcomes verbally, with a new cloud-based platform that uses artificial intelligence to show patients simulate…

This study will look back at medical records of about 1,000 people in the US with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy as their first treatment. Researchers want to see how well the treatment works and what side ef…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This pilot study is testing whether it's possible to run a larger study that focuses on heart disease in women. Researchers will gather information from 176 women aged 25-55 in Ontario who have had certain female-specific health issues like pre-eclampsia, gestational diabetes, or…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

Researchers at Lund University are studying whether psychological resilience, a person's ability to cope with stress, is linked to biological markers in breast cancer patients. They will measure resilience through questionnaires and analyze tumor and blood samples for molecular s…

This observational study looks at fertility decisions and outcomes in young women diagnosed with breast cancer in China. Researchers will follow women who had no children before their diagnosis to see if they later gave birth, and how often they used fertility preservation method…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…

This study looks at 100 women with stage II or III breast cancer to see if proton beam radiation causes less damage to the heart and lungs than standard X-ray radiation. Participants receive either type of radiation as part of a larger trial. Researchers will measure changes in h…

This study looks at how normal breast tissue appears on MRI and mammogram to see if it can help predict breast cancer risk. Researchers are comparing images and health information from over 2,000 women, including those with and without breast cancer. The goal is to better underst…

This trial studies whether small differences in genes affect how patients with small cell lung cancer respond to the chemotherapy drug etoposide and how severe its side effects are. Researchers will analyze DNA from 600 patients who take etoposide capsules, comparing two versions…

This study follows women with early-stage breast cancer who are about to receive paclitaxel chemotherapy, a treatment that often causes nerve damage. Researchers will use smartwatches and a mobile app to track physical activity, sleep, and stress, alongside clinical exams and ski…

This study looks at whether a new scoring system, called the DIEP-MDS, can help predict the risk of blood flow problems and flap failure after DIEP flap breast reconstruction. The score is based on CT scans of the abdomen, measuring features of the blood vessels used in the surge…

This study follows breast cancer patients who have had curative surgery and are receiving hypofractionated radiation therapy—shorter treatment courses lasting one to three weeks. Researchers will track changes in breast skin, fibrosis, cosmetic appearance, and patient-reported ou…

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study is looking at why some people develop persistent pain after breast cancer surgery while others do not. Researchers will follow 220 adults undergoing breast cancer surgery, using questionnaires and a pain sensitivity test to identify risk factors. The goal is to find re…

This study aims to create a large collection of blood and tissue samples from people with breast cancer, as well as those at high risk. The samples will be stored and used for future research to better understand, diagnose, and treat breast cancer. Participants will also be asked…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study explores whether a remote, direct-to-patient approach can improve how people with small cell lung cancer (SCLC) are reached and engaged in clinical research. It involves collecting biospecimens and surveying patients about their preferences and needs regarding new ther…

This study is looking at how triple-negative breast cancer evolves during chemotherapy. Researchers will take biopsies from the tumor before, during, and after treatment to see if the diversity of cancer cells affects how well the tumor responds. The goal is to understand why som…

This study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as wel…

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who…

This study looks at how the drug ribociclib is actually used in everyday medical practice for people with a common type of early breast cancer (HR+/HER2-). Researchers will analyze medical records from thousands of patients to see who gets the drug, how long they take it, and wha…

This study investigates whether bioimpedance analysis, a quick and painless test that measures body water and muscle mass using a weak electrical current, can help predict complications after lung cancer surgery. Researchers will compare these measurements with standard CT scans …

This study examines whether changes in the LKB1 gene can help predict how well people with non-small cell lung cancer respond to treatments like chemotherapy, targeted therapy, and immunotherapy. Researchers will analyze tumor samples and medical records from about 300 patients t…

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whethe…

This study collects extra tissue and a small blood sample from people undergoing standard procedures for lung cancer. Researchers will use these samples to grow miniature versions of the tumors, called organoids, in the lab. The goal is to study how lung cancers grow and change, …

This study looks at how chronic noncommunicable diseases like inflammatory bowel disease and breast cancer impact a person's ability to work. Researchers will follow 200 working-age adults for 12 months, collecting data on health, work performance, and well-being. The goal is to …

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study tests five different reminder strategies to encourage women in Singapore who are overdue for mammograms to get screened. About 12,750 women aged 50-69 who have not had a mammogram in over two years will receive reminders by mail, with some getting a pre-scheduled appoi…

This study looks at how to best collect information about social and behavioral needs (like housing, food, or transportation) from women newly diagnosed with breast cancer. Researchers will compare different screening tools and methods (like chatbots or phone calls) to see which …

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study examines whether medications given during mastectomy to keep blood pressure stable might affect the risk of breast cancer coming back. Researchers will review the records of 250 patients who had mastectomy over five years. They will look at which drugs were used and tr…

This study involves 15 postmenopausal women with metastatic ER+ breast cancer. Researchers are testing a special PET scan that uses a radioactive tracer to see estrogen receptors on tumors. The goal is to find the best way to measure these receptors, which could help doctors know…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study follows over 1,000 people with newly diagnosed non-small cell lung cancer in community cancer clinics. Researchers want to see how many patients receive key biomarker test results before starting treatment, and what barriers (like tissue issues or insurance problems) c…

The FATLAS study is looking at how body fat (adiposity) influences breast cancer at both the whole-body and cellular levels. Researchers will enroll 150 breast cancer patients with different body types (lean, overweight, obese) and collect blood, tumor tissue, and body measuremen…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at the genetic makeup of lung cancers found through low-dose CT screening. Researchers want to understand why some cancers grow quickly and others grow slowly. About 526 people who had surgery for screen-detected lung cancer will provide tissue samples for DNA an…

This study follows over 1,800 adults who had early-stage lung cancer treatment to see how often they get CT scans and whether scanning every 6 months helps them live longer than yearly scans. Researchers will also check if scan frequency differs by race, income, or location. The …

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…